drugset / Trial / NCT07515391

Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery

NCT07515391

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.

Timeline

Start
2019-10-22
Primary completion
2021-05-01
Completion
2026-10-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 10 mg